The DOI matches its Crossref record.
Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG)
Open accessAbstract
In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six patients were ineligible; of the 37 eligible patients, ten had prior radiotherapy and 18 prior surgery. They received 100 mg m-2 in 1 h i.v. every 3 weeks, usually in an outpatient setting. Prophylactic steroids, antihistaminics or antiemetics were not routinely given. Two patients were not evaluable because they withdrew from the study because of a hypersensitivity reaction after the second cycle. The main toxicity was neutropenia (80% of cycles), although infections were rare (4%). One patient died from sepsis during neutropenia. Hypersensitivity reactions necessitating interruption of docetaxel (Taxotere) infusions were found in only 10% of cycles. The overall response rate was 23% with one complete response, and seven partial responses. Stable disease was found in 16 patients. The median duration of response was 36 weeks, and the median survival of all patients was 11 months. Docetaxel (Taxotere) is among the most active drugs for treatment of NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
Rowinsky, M. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.353 · Cited by 721
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Hensley, M. L., Maki, R., Venkatraman, E., Geller, G., Lovegren, M., Aghajanian, C., Sabbatini, P., Tong, W., Barakat, R., & Spriggs, D. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.050 · Cited by 683
He, Q., & Shi, J. (2014) · Advanced Materials · doi:10.1002/adma.201303123 · Cited by 482
Bruno, R., Hille, D., Riva, A., Vivier, N., ten Bokkel Huinnink, W. W., van Oosterom, A. T., Kaye, S. B., Verweij, J., Fossella, F. V., Valero, V, et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.187 · Cited by 423
Self-citationPaclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind
Verweij, J., Clavel, M., & Chevalier, B. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058903 · Cited by 361
Metadata
- Authors
- for the ECTG (Early Clinical Trials Group of the EORTC), Cerny, T., Kaplan, S., Pavlidis, N., Schöffski, P., Epelbaum, R., van Meerbeek, J., Wanders, J., Franklin, H., & Kaye, S.
- Venue
- British Journal of Cancer
- Published
- 1994-08
- Volume
- 70
- Issue
- 2
- Pages
- 384-387
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2058978290
- Cited by
- 160
- References
- 0
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). https://app.cochat.ai/papers/10.1038/bjc.1994.311
- The paper
- for the ECTG (Early Clinical Trials Group of the EORTC), Cerny, T., Kaplan, S., Pavlidis, N., Schöffski, P., Epelbaum, R., van Meerbeek, J., Wanders, J., Franklin, H., & Kaye, S. (1994). Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). British Journal of Cancer. https://doi.org/10.1038/bjc.1994.311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.